Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 2.80M.
Subavaliada
O PE mais recente da empresa é -13.48, em uma faixa percentil baixa de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 115.97M ações, um aumento de 5.67% em relação ao trimestre anterior.
Mantido por Catherine Wood
O Super Investidor Catherine Wood possui 7.98M ações desta empresa.
Alta Atividade de Mercado
A empresa tem maior interesse dos investidores, com uma taxa de giro de 20 dias de 0.92.